Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

NCT05559645 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: DZD9008
DRUG: DZD9008

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]